Imaging biomarkers are essential in oncology clinical trials

Imaging is critical and is being used at all steps of cancer care, from patient diagnosis to his/her follow up during treatment

Images are also critical in clinical trials and are key to evaluate the efficacy of new candidate drugs or innovative therapeutic schemes.

However, image interpretation and management in clinical trials triggers a number of issues such as doubtful reliability of image analysis due to a high variability in image interpretation, censoring bias, and a number of operational issues due to complex image data workflow.

MEDIAN CTIS - CIinical Trial Imaging Services - is the only imaging service offering that standardizes investigator & independent reviews thus:

Reducing variability & censoring bias
Streamlining data management workflow
Enabling sponsors to manage and mine images and lesion data
Providing the ability to extract advanced imaging biomarkers.